1.Relationship of PLXNC1 (rs2272335) polymorphism with genetic susceptibility to primary liver cancer among family clusters in Guangxi and its expression
Chengcheng HE ; Yu'an XIE ; Sailan MAO ; Zheng HUANG ; Lei YAN ; Ruiqiang ZHAO
Chinese Journal of Clinical Oncology 2015;(13):642-647
Objective:To investigate the correlation between plexinC1 (PLXNC1) rs2272335 polymorphism and the family clus-tering genetic susceptibility to primary liver cancer (PLC) in Guangxi and the expression of PLXNC1. Methods:Genotype and alleles of rs2272335 were determined in 20 liver cancer family groups (79 cases) and 10 healthy normal control groups (40 cases) in Fusui County through Time of Flight Mass Spectrometer. Immunohistochemistry detected the PLEXNC1 protein expression. Results:For the alleles of PLXNC1 (rs2272335) site, the risk of hepatocellular carcinoma (HCC) for individuals with [C] allele was 4.16-fold (95%CI=0.37-47.3, P=0.032) compared with that for individuals with [T] allele among the members of the healthy normal control group. The fre-quencies of the [C] and [T] alleles were similar in the HCC patients and the core individuals of liver cancer families (P>0.05). For the genotype of the PLXNC1 (rs2272335) site, the differences in frequencies of TT, TC, and CC genotypes were not statistically significant among the PLC patients and the core individuals of the liver cancer families and normal controls. The PLXNC1 protein expression in HCC (3.12±1.12) was higher than in hepatocellular paracancerous tissues (1.54±0.67) and in benign hepatocellular lesions (1.23±0.87) (P<0.05). Conclusion:The [C] allele of PLXNC1 (rs2272335) site might be the risk gene for the occurrence of PLC family clustering in Guangxi. PLXNC1 protein overexpression was closely correlated with PLC oncogenesis.
2.Epidemiological survey on hypertension among Tibetan monks in Gannan Tibetan Autonomous Prefecture of Gansu Province.
Xinghui LI ; Email: XINGHUI415@163.COM. ; Ping XIE ; Yan QIAO ; Yu'an MA ; Baojuan LI
Chinese Journal of Cardiology 2015;43(12):1088-1091
OBJECTIVETo explore the prevalence, awareness, treatment and control rates of hypertension among Tibetan monks in Gannan Tibetan Autonomous Prefecture of Gansu Province, and to analyze risk factors of hypertension in this population.
METHODSA total of 984 (aged 18 and over) Tibetan monks in Gannan Tibetan Autonomous Prefecture of Gansu Province were included with cluster sampling method from March to June, 2014. General information was obtained by questionnaire and blood pressure was measured. Multivariate logistic regression analysis was applied to analyze the risk factors of blood pressure.
RESULTSPrevalence of hypertension in this population was 19.3% (190/984), and standardized prevalence rate was 21.7%. The prevalence of hypertension were 16.3% (82/502), 21.0% (60/286) and 24.5% (48/196), and standardized prevalence rate was 17.8%, 22.1% and 26.6% among Tibetan monks aged 18-39, 40-59 and ≥60 years, respectively. Rates of awareness, treatment and control of hypertension in Tibetan monks were 9.5% (18/984), 4.2% (8/984)and 1.6% (3/984), respectively. Multivariate logistic regression analysis showed that age, body mass index and family history of hypertension were independent risk factors of hypertension in this population (P<0.01 or 0.05).
CONCLUSIONSPrevalence, awareness, treatment and control rates of hypertension among Tibetan monks in Gannan Tibetan Autonomous Prefecture of Gansu Province are relatively low. Age, body mass index and family history of hypertension are risk factors of hypertension in this population.
Blood Pressure ; Body Mass Index ; Humans ; Hypertension ; epidemiology ; Monks ; Prevalence ; Reference Standards ; Risk Factors ; Surveys and Questionnaires
3.Clinical analysis on platinum-based combined chemotherapeutical regimens for treating relapsed or refractory non-Hodgkin lymphoma
Hongxue WANG ; Meilin CHEN ; Fanghui QIN ; Wenxian ZHOU ; Yuxian JIA ; Jun CHEN ; Hong CEN ; Yu'an XIE ; Yongkui LU ; Weimin XIE
Chongqing Medicine 2018;47(5):618-621,625
Objective To evaluate the efficacy and adverse reactions of platinum-based combined chemotherapeutical regimens in treating relapsed or refractory non-Hodgkin lymphoma(NHL).Methods The clinical data of 68 patients with relapsed or refractory NHL treated with platinum-based combined chemotherapeutical regimens in the Affiliated Tumor Hospital of Guangxi Medical University from January 2008 to December 2014 were retrospectively analyzed.The curative effect of related regimens,adverse reactions and related influence factors were analyzed.Results Sixty-eight cases received 283 cycles of chemotherapy.In all cases,11 cases(16.18 %) achieved the complete response(CR),31 cases(45.59 %) achieved the partial response(PR),the overall response rate(ORR) was 61.76%;the median progression-free survival(PFS) was 6.51 months(95%CI:4.97-8.04 months).ORR and PFS in the cases of stage Ⅱ-Ⅲ,IPI score 0-2 and receiving only one chemotherapeutical regimen were superior to those in the cases of corresponding subgroup(P<0.05);ORR and PFS had no statistical difference between the B cells lymphoma and Tcells lymphoma(P>0.05).The medion PFS in the combined R group was 11.16 months,which was longer than 5.84 months in the non-combined R group(P =0.004).The major adverse events (stage Ⅱ-Ⅲ) included leukopenia (41.18 %),thrombocytopenia (27.94%),hemoglobin decrease(11.76%),vomiting(8.82%) and diarrhea(1.47%).Conclusion The platinum-based combined chemotherapeutical regimens are effective with good safety in the treatment of relapsed or refractory NHL.
4.Application of glycan microarrays in cancer research.
Beining XU ; Yinkun LIU ; Yu'an XIE
Chinese Journal of Biotechnology 2020;36(11):2313-2326
Glycosylation is one of the common post-translational modifications of proteins to regulate the ability of tumor invasion, metastasis and tumor heterogeneity by interacting with glycan-binding proteins such as lectins and antibodies. Glycan microarray can be constructed by chemical synthesis, chemical-enzyme synthesis or natural glycan releasing. Glycan microarray is an essential analytical tool to discover the interaction between glycan and its binding proteins. Here we summarize the standard techniques to construct glycan microarray for the application in cancer vaccine, monoclonal antibody and diagnostic markers.
Antibodies, Monoclonal
;
Glycosylation
;
Lectins/metabolism*
;
Microarray Analysis
;
Neoplasms
;
Polysaccharides